about
Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention?Current perspectives on HIV-1 antiretroviral drug resistanceEvolutionary rescue: linking theory for conservation and medicineHIV Drug Resistance: Problems and PerspectivesCapturing the Reaction Pathway in Near-Atomic-Resolution Crystal Structures of HIV-1 ProteaseNovel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 ProteaseA mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptaseProlonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CHigh drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in SpainScreening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in ChinaLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensLong-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort studyIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisSignificantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram dataPrevalence of transmitted HIV drug resistance in Iran between 2010 and 2011Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceTrends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in SpainA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyHIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern BrazilDB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOsHIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in GhanaIdentification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strainsHigh-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimenPrevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failureThe HIVToolbox 2 web system integrates sequence, structure, function and mutation analysisResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionHIV-1 pol diversity among female bar and hotel workers in Northern TanzaniaEstimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in GermanyHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaEvaluation of dried blood spots collected on filter papers from three manufacturers stored at ambient temperature for application in HIV-1 drug resistance monitoringHIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, ChinaPhylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men.Viral and Host Characteristics of Recent and Established HIV-1 Infections in Kisumu based on a Multiassay Approach.Data-intensive analysis of HIV mutations.In vivo mutation rates and the landscape of fitness costs of HIV-1.Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis
P2860
Q26796151-29B1F9CC-3F6B-48AC-89A8-50AEED4051CEQ26852626-93048D66-CD35-4448-9149-2772F357221FQ26862297-496C23E8-CB6C-470A-BD97-C3AADA2BFE64Q26864534-7A187BC7-97DC-4D1F-A435-EED8D5ECD733Q27672873-B39D8072-034A-4C94-BD28-BE6E007F10FFQ27675818-6276A892-2F0F-452C-B6D8-C0BB00E492D3Q27683249-59365FD7-4D81-4A49-B4A2-A81F53E3EF2DQ28484064-D8E32461-64D5-4DFE-B7DA-CDBB6D32E067Q28484213-E59BAF97-DC23-488C-A558-59D7856415F0Q28484394-F452BC85-0451-4C97-A55F-EF7D54DA57DCQ28485108-836307DA-F243-480F-B21D-0A7F3F4329DCQ28485321-0ECA4D3C-1F61-4443-AC9C-880357FADCD4Q28485373-C0913839-FFAE-4FE3-8025-2BD696C4AB40Q28486262-BA3F2E6D-0DA7-4CF3-B46F-772CF95CDC14Q28486299-36DDDF0E-0EAC-447E-94CC-C0C9B999E981Q28486583-038C94B2-3714-4633-88B5-A454D47CD81FQ28488527-33914DE4-B6E4-40EE-B082-1E09C2B3CBE4Q28488769-021AD731-0CBA-4AE3-B272-F1E7ABC4D93AQ28533216-F194A18E-C029-41CF-B9D8-A790B0B1D0B5Q28533996-B3B39BA1-F7A1-4DC7-80BA-389B73DEECA0Q28534423-B41C5BFD-EB71-4788-948A-161AF12F4DCAQ28534576-2ED7F875-0EFB-4965-B526-1721020917F4Q28535401-10A1D425-B2A1-46B3-9D6C-6EEC5A896238Q28535421-B8491DF0-579A-4874-A900-7DBEC8A3928EQ28537991-79A47401-22B2-4F4C-86B3-091B0DA6A8FAQ28538692-F6D4DC64-D150-43BF-A913-6E1425654398Q28539186-283922E8-79A8-4989-92A6-7344FC1E7163Q28539260-80A38B18-4C7A-47BC-9D0D-CE5E162E2ABEQ28539563-17FF4699-CD01-4DD5-B85F-03A38486D43FQ28540536-9367AE3A-1E8C-460D-B190-2C436E0F27EDQ28542508-448A8207-8549-49AA-913B-1F4BE09E73F8Q28543358-9B7AFC1D-1BA8-4820-9F71-7FAB75E3A392Q28543688-EAEAB351-81F6-4E56-92CB-73379CBBB4B9Q28550283-2A760387-87C4-4444-A052-D01F4A4A4C62Q30670919-193BADAC-000D-4CD8-B026-8C29CEA6100FQ30830042-8278B635-4836-4F14-8B53-86B702BD9733Q30887525-177EE3B8-1AF5-489A-A6E1-C78943D73416Q33589204-E10E68D5-966D-46E0-9354-898D016242FFQ33622927-12A40EEC-14DC-4C3B-AACD-B8271E9CD86AQ33624953-9FF464A8-2F06-47EE-B209-137F3C7BBD51
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
2011 update of the drug resistance mutations in HIV-1.
@en
2011 update of the drug resistance mutations in HIV-1.
@nl
type
label
2011 update of the drug resistance mutations in HIV-1.
@en
2011 update of the drug resistance mutations in HIV-1.
@nl
prefLabel
2011 update of the drug resistance mutations in HIV-1.
@en
2011 update of the drug resistance mutations in HIV-1.
@nl
P2093
P1476
2011 update of the drug resistance mutations in HIV-1
@en
P2093
Annemarie M Wensing
Deenan Pillay
Douglas D Richman
Robert Shafer
Roger Paredes
Victoria A Johnson
Vincent Calvez
P304
P577
2011-11-01T00:00:00Z